The success of Sildenafil initially drove a surge for major pharmaceutical companies, but recent developments present a murky scenario for those considering a stake. Lower-cost competitors are eroding revenue, and https://dillanwvmm289222.blogs-service.com/72288143/the-blue-pill-and-the-pharmaceutical-industry-a-risky-play